Ensho Saisei
Online ISSN : 1880-5795
Print ISSN : 1346-8022
ISSN-L : 1346-8022
Dose a pharmaceutical company have any interest in the field of developing regenerative medicine?
Toshiyuki Chiba
Author information
Keywords: QOL, TLO, CPC, GMP, clinical trial
JOURNAL FREE ACCESS

2002 Volume 22 Issue 1 Pages 39-46

Details
Abstract
A patient needs the frontier medicine, for example, regenerative medicine, gene therapy and pharmacogenomics. We believe that the regenerative medicine fits for that needs. So, we will discuss about researching and developing a regenerative medicine.
At first, we have to prepare the infrastructure of clinical trial and investment for developing the regenerative medicine. And we will have to build the consortium that contains clinical research center and support center for regenerative medicine. We will call that consortium “regenerative medicine development consortium”.
The clinical research center has a cell processing center, cell and tissue supply center, cell resource development center and cell & tissue bank.
A support center for regenerative medicine has new concept hospital, rehabilitation center, job training center, volunteer organization in support of regenerative medicine and patients.
Content from these authors
© The Japanese Society of Inflammation and Regeneration
Previous article Next article
feedback
Top